Mark Vignola | Intercept Pharmaceuticals, Inc. |
Mark E. Pruzanski, M.D. | Intercept Pharmaceuticals, Inc. |
Richard Kim | Intercept Pharmaceuticals, Inc. |
Lisa Bright | Intercept Pharmaceuticals, Inc. |
Sandip Kapadia | Intercept Pharmaceuticals, Inc. |
Rachel L. McMinn, Ph.D. | Intercept Pharmaceuticals, Inc. |
Michael J. Yee | Jefferies LLC |
Brian Abrahams | RBC Capital Markets LLC |
Alethia Young | Credit Suisse Securities (NYSE:USA) LLC |
Ritu Baral | Cowen & Co. LLC |
Aspen Mori | Bank of America Merrill Lynch |
Jay Olson | Oppenheimer & Co., Inc. |
Andrew Scott Berens | Morgan Stanley & Co. LLC |
Alan Carr | Needham & Co. LLC |
Dae Gon Ha | Leerink Partners LLC |
Joel L. Beatty | Citigroup Global Markets, Inc. |
Liisa A. Bayko | JMP Securities LLC |
Brian P. Skorney | Robert W. Baird & Co., Inc. |
Thank you for joining the Intercept Pharmaceuticals' 2017 Third Quarter Financial Results Conference Call. All participants are now in listen-only mode.
Following opening remarks, Intercept management will open the lines for a question-and-answer period. Please be advised that this call is being recorded at the company's request, and a webcast of this call will be archived on the company's website for two weeks from today's date. I would now like to introduce Dr.